BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma

Gao, Yushun; Wang, Bing; Gao, Shugeng

doi:10.1371/journal.pone.0156701

Cited by 17 publications

(16 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BRD7 is a multifunctional gene, exhibiting its functions through several pathways (6). As a tumor suppressor, BRD7 inhibited cancer cell growth via phosphoinositide 3-kinase (PI3K)/Akt, ER stress, ERK and hypoxia-inducible factor α (HIF1α)/lactate dehydrogenase A signaling (10,34–36). Furthermore, BRD7 regulated glucose homeostasis through glycogen synthase kinase 3β and X-box binding protein 1 (37,38).…”

Section: Discussionmentioning

confidence: 99%

Bromodomain‑containing protein�7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein

Ma¹,

Niu

Zhou

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

Our previous study demonstrated that bromodomain-containing protein 7 (BRD7) inhibits cell proliferation and tumor growth, restoring the expression of B-cell lymphoma 2 antagonist/killer (Bak) sensitized breast cancer cells to paclitaxel. However, the association between BRD7 and paclitaxel sensitization, as well as BRD7 and Bak in breast cancer remains unknown. In the present study, immunochemical staining was performed to measure the expression of BRD7 and Bak in breast cancer tissues. Cell Counting Kit-8 assay, flow cytometry and tumor xenograft procedures were performed to evaluate the biological role of BRD7 and Bak in breast cancer cells. Western blotting, reverse transcription-quantitative polymerase chain reaction, chromatin immunoprecipitation and luciferase reporter assays were also performed. BRD7 was positively correlated with Bak levels in breast cancer tissues, and the survival rate of patients with low Bak and BRD7 expression was significantly lower than that of patients with high Bak and BRD7 expression. In addition, BRD7 activated Bak promoter activity and induced Bak expression in an indirect manner. Furthermore, ectopic expression of BRD7 inhibited cell proliferation, tumor growth and sensitized cancer cells to paclitaxel, while knockdown of Bak abolished BRD7-mediated inhibitory effects on cell proliferation and paclitaxel sensitization in breast cancer cells whether in vitro and in vivo. The results demonstrated that BRD7 inhibits cell proliferation and sensitizes breast cancer cells to paclitaxel by activating Bak; they also provide promising targets for the diagnosis and treatment of breast cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Bromodomain‑containing protein�7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein

Ma¹,

Niu

Zhou

et al. 2018

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…These data may indicate that BRD7 is associated with PCa progression. In addition to PCa, upregulation of BRD7 has been associated with decreased cell proliferation and migration in lung adenocarcinoma and may exert antitumor effects by activating the phosphorylation of ERK (34). The current study provides evidence that BRD7 may be used as an efficient biomarker for PCa diagnosis and prognosis.…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of bromodomain‑containing protein 7 and its association with tumor progression in prostate cancer

et al. 2018

View full text Add to dashboard Cite

Prostate cancer (PCa) is a common malignancy in males. The current study assessed the clinical significance of bromodomain-containing protein 7 (BRD7) and its association with PCa tumor progression. Serum and tissue expression levels of BRD7 were analyzed by reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic (ROC) analysis was used to evaluate the diagnostic value of BRD7. Kaplan-Meier survival analysis and Cox regression analysis were performed to assess the prognostic performance of BRD7. The association of BRD7 with cell behavior was investigated by transfection with a pcDNA3.1-BRD7 vector. The results revealed that serum and tissue BRD7 expression levels were significantly decreased in PCa samples compared with normal controls (P<0.001). BRD7 expression was significantly associated with the pathological stage (P=0.037), lymph node metastasis (P=0.009) and TNM stage (P=0.010). An area under the ROC curve of 0.864 was obtained, with a sensitivity and specificity of 77.0 and 83.3%, respectively. Low BRD7 expression was significantly associated with a shorter survival time in both overall survival analysis (P=0.003) and cancer-specific survival analysis (P=0.029). Furthermore, BRD7 appeared to serve as an independent prognostic factor for PCa. The proliferation, migration and invasion of PCa cells were suppressed by BRD7 overexpression. In summary, downregulation of BRD7 in PCa may be involved in tumor progression and serve as an effective diagnostic and prognostic biomarker.

show abstract

“…Lung cancer, with high morbidity and mortality rate, ranks first among all the malignancies in developed and developing countries such as India, Europe, China and the USA [ 41 ]. Various tumor suppressor genes associated with lung cancer include, tumor suppressor gene TP53 [ 42 ], Adenomatous polyposis coli (APC) [ 43 ], Bromodomain containing 7 (BRD7) [ 44 ], Cyclin Dependent Kinase Inhibitor 2A (CDKN2A) [ 45 ] and NM23 [ 46 ]. Proto-oncogenes constituting lung cancer are receptor tyrosine kinase (RTK) [ 47 ], MYC [ 48 ], JUN [ 49 ], FOS [ 50 ], RAF1 [ 51 ] and ERBB1&2 [ 52 ].…”

Section: Applications Of Crispr In Cancer Researchmentioning

confidence: 99%

Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications

2021

View full text Add to dashboard Cite

BRD7 Acts as a Tumor Suppressor Gene in Lung Adenocarcinoma

Cited by 17 publications

References 31 publications

Bromodomain‑containing protein�7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein

Bromodomain‑containing protein�7 sensitizes breast cancer cells to paclitaxel by activating Bcl2‑antagonist/killer protein

Clinical significance of bromodomain‑containing protein 7 and its association with tumor progression in prostate cancer

Will CRISPR-Cas9 Have Cards to Play Against Cancer? An Update on its Applications

Contact Info

Product

Resources

About